UK markets open in 7 hours 32 minutes
  • NIKKEI 225

    29,262.76
    -296.34 (-1.00%)
     
  • HANG SENG

    29,880.42
    +784.56 (+2.70%)
     
  • CRUDE OIL

    60.96
    -0.32 (-0.52%)
     
  • GOLD FUTURES

    1,709.70
    -6.10 (-0.36%)
     
  • DOW

    31,270.09
    -121.43 (-0.39%)
     
  • BTC-GBP

    36,102.93
    +1,336.55 (+3.84%)
     
  • CMC Crypto 200

    1,014.06
    +25.96 (+2.63%)
     
  • ^IXIC

    12,997.75
    -361.04 (-2.70%)
     
  • ^FTAS

    3,808.24
    +36.56 (+0.97%)
     

Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

·7-min read

Takeda Pharmaceutical Company Limited / Key word(s): Forecast
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

04-Feb-2021 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

Osaka, Japan, February 4, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2021*1, as below.

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2021


(millions of yen)

 

Revenue

Core
Operating
Profit

Operating
profit

Profit before
income taxes

Net profit attributable
to owners of
the Company

Basic earnings
per share

Core EPS

Previous Forecast (A)***

3,250,000

984,000

434,000

258,000

124,000

79.39 yen

420 yen

Revised Forecast (B)

3,250,000

984,000

434,000

258,000

180,500

115.56 yen

420 yen

Discrepancy (B-A)

+56,500

Change %

+45.6%

 

*** Announced on October 29, 2020.

2. Reasons for Revision

The forecast for net profit for the period attributable to owners of the Company has been increased by 56.5 billion JPY, or 45.6%, to 180.5 billion JPY. This is primarily due to updated tax rate assumptions reflecting lower tax costs associated with on-going integration and optimization of the legal entities within our organizational structure.

Accordingly, the EPS forecast has been increased by 36.17 JPY, or 45.6%, to 115.56 JPY.

*1 In August 2020, Takeda announced that it has entered into an agreement to divest Takeda Consumer Healthcare Company Limited ("TCHC"), a wholly-owned subsidiary of Takeda primarily focused on the consumer health care market in Japan, to Blackstone for a total value of 242.0 billion JPY*2. The transaction is expected to close by March 31, 2021, subject to customary legal and regulatory closing conditions. Takeda anticipates a pre-tax gain of approximately 140.0 billion JPY on the sale of shares of TCHC, to be recognized when the transfer of shares is executed and completed, however, it was not included in the previous forecast nor is it included in the revised forecast for the fiscal year ending March 31, 2021. In consideration of the uncertainty of the exact timing of deal closure, Takeda will continue to assess the appropriate timing of inclusion of this event into its forecast.

*2 Enterprise value. Actual transfer price will be determined after adjustment for items including net debt and working capital.

3. Management Guidance

There are no changes to Management Guidance.

 

Guidance as of
October 29, 2020

Guidance as of
February 4, 2021

Underlying Revenue Growth

Low-single-digit growth

Low-single-digit growth

Underlying Core Operating Profit Growth

High-single-digit growth

High-single-digit growth

Underlying Core Operating Profit Margin

Low-30s%

Low-30s%

Underlying Core EPS Growth

Low-teen growth

Low-teen growth

 

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit https://www.takeda.com.

Contacts:

Investor Relations
Christopher O'Reilly, +81-(0)3-3278-2306
takeda.ir.contact@takeda.com

Media Relations
Kazumi Kobayashi, +81 (0)3-3278-2095
kazumi.kobayashi@takeda.com
 

 

Important Notice
For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at:
https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

###

04-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-Chrome, Chuo-ku

103-8668 Tokyo

Japan

Phone:

+81-3-3278-2039

E-mail:

hisashi.tokinoya@takeda.com

ISIN:

JP3463000004, XS1843449981, XS1843450138, XS1843449049, XS1843449809, XS1843449122, XS1843449395,

WKN:

853849

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1165351


 

End of Announcement

DGAP News Service

show this
show this